TG THERAPEUTICS, INC.
Commercializes B-cell therapies like BRIUMVI® for multiple sclerosis & autoimmune diseases.
TGTX | US
Overview
Corporate Details
- ISIN(s):
- US88322Q1085
- LEI:
- Country:
- United States of America
- Address:
- 2 GANSEVOORT STREET, 9TH FLOOR, 10014 NEW YORK
- Website:
- https://www.tgtherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments. The company leverages scientific advances in B-cell biology to develop therapies for B-cell-mediated diseases. Its primary commercial product is BRIUMVI® (ublituximab), a monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. TG Therapeutics is dedicated to advancing its pipeline to address unmet medical needs in autoimmune diseases and hematologic malignancies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all TG THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TG THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TG THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
